

**NC Medicaid and NC Health  
Choice Pharmacy Prior  
Approval Request for Juxtapid**

**Beneficiary Information**

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

**Prescriber Information**

6. Prescribing Provider NPI #: \_\_\_\_\_  
7. Requester Contact Information - Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_

**Drug Information**

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_ 10. Quantity Per 30 Days: \_\_\_\_\_  
11. Length of Therapy (in days):  up to 30 Days  60 Days  90 Days  120 Days  180 Days  365 Days

**Clinical Information**

1. Has the recipient been diagnosed with homozygous familial hypercholesterolemia (HoFH)?  Yes  No
2. Is the recipient enrolled in the Juxtapid REMS program?  Yes  No
3. Is the recipient at least 18 years old or older?  Yes  No
4. Is the recipient female?  Yes  No (if Yes, then answer 4a; if No then move to question 4a. If female, has a negative pregnancy test been obtained?  Yes  No
5. Has a measurement of the recipient's ALT, AST, alkaline phosphatase, and total bilirubin been obtained before initiating treatment?  Yes  No
  - 5a. ALT level: \_\_\_\_\_ (U/L)
  - 5b. AST level: \_\_\_\_\_ (U/L)
  - 5c. Alkaline phosphatase level: \_\_\_\_\_ (U/L)
  - 5d. Bilirubin level: \_\_\_\_\_ (mg/dL)
6. For reauthorization:
  - 6a. During the first year, has the recipient received liver-related tests (ALT and AST, at a minimum) prior to each increase in dose or monthly, whichever occurs first?  Yes  No
  - 6b. After the first year, has the recipient received these tests at least every 3 months and before any increase in dose?  Yes  No
7. Failed two preferred drug(s). List preferred drugs failed: \_\_\_\_\_
  - 7a. Allergic Reaction: \_\_\_\_\_
  - 7b. Drug-to-drug interaction. Please describe reaction: \_\_\_\_\_
8. Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information: \_\_\_\_\_
9. Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s). Please provide Clinical information: \_\_\_\_\_
10. Age specific indications. Please give patient age and explain: \_\_\_\_\_
11. Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a general reference: \_\_\_\_\_
12. Unacceptable clinical risk associated with therapeutic change. Please explain: \_\_\_\_\_



I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

Fax this form to **1-800-678-3189**  
Pharmacy PA Call Center: **1-866-799-5318**